Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $243 | In Stock | |
5 mg | $753 | In Stock | |
10 mg | $1,180 | In Stock | |
25 mg | $1,750 | In Stock | |
50 mg | $2,350 | In Stock |
Description | Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). |
Targets&IC50 | MC38 colon cancer cells (mouse):1 nM(EC50) |
In vitro | Nidanilimab (CAN04; 20 µg/mL) exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) with glycoengineering-enhanced properties in mouse MC38 colon cancer cells, with an EC50 of less than 1 nM[2]. Nidanilimab (20 µg/mL) blocks the IL1α and IL1β signaling pathways in mouse MC38 colon cancer cells, with IC50 values of 3.9 nM and 4.1 nM, respectively[2]. |
In vivo | In nude C57Bl/6 mice, Nidanilimab (CAN04; 10 mg/kg; intraperitoneal injection) enhances the efficacy of two commonly used platinum-based chemotherapy drugs, cisplatin with gemcitabine and carboplatin with gemcitabine[1]. |
Alias | CAN04 |
Molecular Weight | 150 kDa |
Cas No. | 2171061-85-9 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.